

- B.T., Maciver, S.K., Dormitzer, P.R., and Beggs, A.H. (2007). Nemaline myopathy with minicores caused by mutation of the CFL2 gene encoding the skeletal muscle actin-binding protein, cofilin-2. *Am. J. Hum. Genet.* *80*, 162–167.
5. Lehtokari, V.L., Pelin, K., Sandbacka, M., Ranta, S., Donner, K., Muntoni, F., Sewry, C., Angelini, C., Bushby, K., Van den Bergh, P., et al. (2006). Identification of 45 novel mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. *Hum. Mutat.* *27*, 946–956.
 6. Johnston, J.J., Kelley, R.I., Crawford, T.O., Morton, D.H., Agarwala, R., Koch, T., Schäffer, A.A., Francomano, C.A., and Biesecker, L.G. (2000). A novel nemaline myopathy in the Amish caused by a mutation in troponin T1. *Am. J. Hum. Genet.* *67*, 814–821.
 7. Donner, K., Ollikainen, M., Ridanpää, M., Christen, H.J., Goebel, H.H., de Visser, M., Pelin, K., and Wallgren-Pettersson, C. (2002). Mutations in the beta-tropomyosin (TPM2) gene—a rare cause of nemaline myopathy. *Neuromuscul. Disord.* *12*, 151–158.
 8. Laing, N.G., Wilton, S.D., Akkari, P.A., Dorosz, S., Boundy, K., Kneebone, C., Blumbergs, P., White, S., Watkins, H., Love, D.R., et al. (1995). A mutation in the alpha tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy. *Nat. Genet.* *9*, 75–79.
 9. Sambuughin, N., Yau, K.S., Olivé, M., Duff, R.M., Bayarsaikhan, M., Lu, S., Gonzalez-Mera, L., Sivadurai, P., Nowak, K.J., Ravenscroft, G., et al. (2010). Dominant mutations in KBTBD13, a member of the BTB/Kelch family, cause nemaline myopathy with cores. *Am. J. Hum. Genet.* *87*, 842–847.
 10. Sambuughin, N., Swietnicki, W., Techtmann, S., Matrosova, V., Wallace, T., Goldfarb, L., and Maynard, E. (2012). KBTBD13 interacts with Cullin 3 to form a functional ubiquitin ligase. *Biochem. Biophys. Res. Commun.* *421*, 743–749.
 11. Lammens, M., Moerman, P., Fryns, J.P., Lemmens, F., van de Kamp, G.M., Goemans, N., and Dom, R. (1997). Fetal akinesia sequence caused by nemaline myopathy. *Neuropediatrics* *28*, 116–119.
 12. Lacson, A.G., Donaldson, G., Barness, E.G., Ranells, J.D., and Pomerance, H.H. (2002). Infant with high arched palate, bell-shaped chest, joint contractures, and intrauterine fractures. *Pediatr. Pathol. Mol. Med.* *21*, 569–584.
 13. Ravenscroft, G., Jackaman, C., Bringans, S., Papadimitriou, J.M., Griffiths, L.M., McNamara, E., Bakker, A.J., Davies, K.E., Laing, N.G., and Nowak, K.J. (2011). Mouse models of dominant ACTA1 disease recapitulate human disease and provide insight into therapies. *Brain* *134*, 1101–1115.
 14. Abecasis, G.R., Cherny, S.S., Cookson, W.O., and Cardon, L.R. (2002). Merlin—rapid analysis of dense genetic maps using sparse gene flow trees. *Nat. Genet.* *30*, 97–101.
 15. Ravenscroft, G., Thompson, E.M., Todd, E.J., Yau, K.S., Kresoje, N., Sivadurai, P., Friend, K., Riley, K., Manton, N.D., Blumbergs, P., et al. (2013). Whole exome sequencing in foetal akinesia expands the genotype-phenotype spectrum of GBE1 glycogen storage disease mutations. *Neuromuscul. Disord.* *23*, 165–169.
 16. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* *38*, e164.
 17. Harrow, J., Denoeud, F., Frankish, A., Reymond, A., Chen, C.K., Chrast, J., Lagarde, J., Gilbert, J.G., Storey, R., Swarbreck, D., et al. (2006). GENCODE: producing a reference annotation for ENCODE. *Genome Biol.* *7(Suppl 1)*, S4.1–S4.9.
 18. Garritano, S., Gemignani, F., Voegelé, C., Nguyen-Dumont, T., Le Calvez-Kelm, F., De Silva, D., Lesueur, F., Landi, S., and Tavtigian, S.V. (2009). Determining the effectiveness of High Resolution Melting analysis for SNP genotyping and mutation scanning at the TP53 locus. *BMC Genet.* *10*, 5.
 19. Doi, H., Yoshida, K., Yasuda, T., Fukuda, M., Fukuda, Y., Morita, H., Ikeda, S., Kato, R., Tsurusaki, Y., Miyake, N., et al. (2011). Exome sequencing reveals a homozygous SYT14 mutation in adult-onset, autosomal-recessive spinocerebellar ataxia with psychomotor retardation. *Am. J. Hum. Genet.* *89*, 320–327.
 20. Schymkowitz, J., Borg, J., Stricher, F., Nys, R., Rousseau, F., and Serrano, L. (2005). The FoldX web server: an online force field. *Nucleic Acids Res.* *33(Web Server issue)*, W382–W388.
 21. Van Durme, J., Delgado, J., Stricher, F., Serrano, L., Schymkowitz, J., and Rousseau, F. (2011). A graphical interface for the FoldX forcefield. *Bioinformatics* *27*, 1711–1712.
 22. Nowak, K.J., Ravenscroft, G., Jackaman, C., Filipovska, A., Davies, S.M., Lim, E.M., Squire, S.E., Potter, A.C., Baker, E., Clément, S., et al. (2009). Rescue of skeletal muscle alpha-actin-null mice by cardiac (fetal) alpha-actin. *J. Cell Biol.* *185*, 903–915.
 23. Ravenscroft, G., Nowak, K.J., Jackaman, C., Clément, S., Lyons, M.A., Gallagher, S., Bakker, A.J., and Laing, N.G. (2007). Dissociated flexor digitorum brevis myofiber culture system—a more mature muscle culture system. *Cell Motil. Cytoskeleton* *64*, 727–738.
 24. Ruparelina, A.A., Zhao, M., Currie, P.D., and Bryson-Richardson, R.J. (2012). Characterization and investigation of zebrafish models of filamin-related myofibrillar myopathy. *Hum. Mol. Genet.* *21*, 4073–4083.
 25. Zeller, J., Schneider, V., Malayaman, S., Higashijima, S., Okamoto, H., Gui, J., Lin, S., and Granato, M. (2002). Migration of zebrafish spinal motor nerves into the periphery requires multiple myotome-derived cues. *Dev. Biol.* *252*, 241–256.
 26. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., and McVean, G.A.; 1000 Genomes Project Consortium. (2012). An integrated map of genetic variation from 1,092 human genomes. *Nature* *491*, 56–65.
 27. Kimura, M., and Ota, T. (1973). The age of a neutral mutant persisting in a finite population. *Genetics* *75*, 199–212.
 28. Guerois, R., Nielsen, J.E., and Serrano, L. (2002). Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. *J. Mol. Biol.* *320*, 369–387.
 29. Embree, E.J. (2007). The identification and characterization of MKRP, a novel kelch related protein. PhD Thesis, Graduate School of Biomedical Sciences, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX. <http://repositories.tdl.org/utswmed-ir/bitstream/handle/2152.5/226/embreelaurence.pdf?sequence=3>.
 30. Lehnert, S.A., Byrne, K.A., Reverter, A., Natrass, G.S., Greenwood, P.L., Wang, Y.H., Hudson, N.J., and Harper, G.S. (2006). Gene expression profiling of bovine skeletal muscle in response to and during recovery from chronic and severe undernutrition. *J. Anim. Sci.* *84*, 3239–3250.
 31. Prag, S., and Adams, J.C. (2003). Molecular phylogeny of the kelch-repeat superfamily reveals an expansion of BTB/kelch proteins in animals. *BMC Bioinformatics* *4*, 42.
 32. Cirak, S., von Deimling, F., Sachdev, S., Errington, W.J., Herrmann, R., Bönnemann, C., Brockmann, K., Hinderlich, S.,

- Lindner, T.H., Steinbrecher, A., et al. (2010). Kelch-like homologue 9 mutation is associated with an early onset autosomal dominant distal myopathy. *Brain* 133, 2123–2135.
33. Furukawa, M., He, Y.J., Borchers, C., and Xiong, Y. (2003). Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases. *Nat. Cell Biol.* 5, 1001–1007.
 34. Canning, P., Cooper, C.D., Krojer, T., Murray, J.W., Pike, A.C., Chaikuad, A., Keates, T., Thangaratnarajah, C., Hojzan, V., Marsden, B.D., et al. (2013). Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. *J. Biol. Chem.* 288, 7803–7814.
 35. Mrosek, M., Labeit, D., Witt, S., Heerklott, H., von Castelmur, E., Labeit, S., and Mayans, O. (2007). Molecular determinants for the recruitment of the ubiquitin-ligase MuRF-1 onto M-line titin. *FASEB J.* 21, 1383–1392.
 36. Ravenscroft, G., Sollis, E., Charles, A.K., North, K.N., Baynam, G., and Laing, N.G. (2011). Fetal akinesia: review of the genetics of the neuromuscular causes. *J. Med. Genet.* 48, 793–801.
 37. Quinn, C.M., Wigglesworth, J.S., and Heckmatt, J. (1991). Lethal arthrogryposis multiplex congenita: a pathological study of 21 cases. *Histopathology* 19, 155–162.

De Novo Mutations in *GNAO1*, Encoding a $G\alpha_o$ Subunit of Heterotrimeric G Proteins, Cause Epileptic Encephalopathy

Kazuyuki Nakamura,^{1,2,9} Hirofumi Kodera,^{1,9} Tenpei Akita,^{3,9} Masaaki Shiina,⁴ Mitsuhiro Kato,² Hideki Hoshino,⁵ Hiroshi Terashima,⁵ Hitoshi Osaka,⁶ Shinichi Nakamura,⁷ Jun Tohyama,⁸ Tatsuro Kumada,³ Tomonori Furukawa,³ Satomi Iwata,³ Takashi Shiihara,^{2,10} Masaya Kubota,⁵ Satoko Miyatake,¹ Eriko Koshimizu,¹ Kiyomi Nishiyama,¹ Mitsuko Nakashima,¹ Yoshinori Tsurusaki,¹ Noriko Miyake,¹ Kiyoshi Hayasaka,² Kazuhiro Ogata,⁴ Atsuo Fukuda,³ Naomichi Matsumoto,^{1,*} and Hiroto Saitsu^{1,*}

Heterotrimeric G proteins, composed of α , β , and γ subunits, can transduce a variety of signals from seven-transmembrane-type receptors to intracellular effectors. By whole-exome sequencing and subsequent mutation screening, we identified de novo heterozygous mutations in *GNAO1*, which encodes a $G\alpha_o$ subunit of heterotrimeric G proteins, in four individuals with epileptic encephalopathy. Two of the affected individuals also showed involuntary movements. Somatic mosaicism (approximately 35% to 50% of cells, distributed across multiple cell types, harbored the mutation) was shown in one individual. By mapping the mutation onto three-dimensional models of the $G\alpha$ subunit in three different complexed states, we found that the three mutants (c.521A>G [p.Asp174Gly], c.836T>A [p.Ile279Asn], and c.572_592del [p.Thr191_Phe197del]) are predicted to destabilize the $G\alpha$ subunit fold. A fourth mutant (c.607G>A), in which the Gly203 residue located within the highly conserved switch II region is substituted to Arg, is predicted to impair GTP binding and/or activation of downstream effectors, although the p.Gly203Arg substitution might not interfere with $G\alpha$ binding to G-protein-coupled receptors. Transient-expression experiments suggested that localization to the plasma membrane was variably impaired in the three putatively destabilized mutants. Electrophysiological analysis showed that $G\alpha_o$ -mediated inhibition of calcium currents by norepinephrine tended to be lower in three of the four $G\alpha_o$ mutants. These data suggest that aberrant $G\alpha_o$ signaling can cause multiple neurodevelopmental phenotypes, including epileptic encephalopathy and involuntary movements.

Introduction

Epileptic encephalopathy is a group of neurological disorders characterized by severe and progressive cognitive and behavioral impairments, which are most likely caused or made worse by epileptic activity.¹ Ohtahara syndrome (OS [MIM 308350 and 612164]) is the most severe and the earliest form of epileptic encephalopathy and is characterized by tonic spasms mainly in the neonatal period, seizure intractability, and a suppression-burst pattern on electroencephalography (EEG).² De novo mutations in three genes, *ARX* (MIM 300382), *STXBP1* (MIM 602926), and *KCNQ2* (MIM 602235), have been reported in individuals with OS.^{3–6}

Heterotrimeric guanine-binding proteins (G proteins) are composed of α , β , and γ subunits. In its basal state, $G\alpha$ is bound with guanosine diphosphate (GDP) and forms the $G\alpha\beta\gamma$ complex. When a seven-transmembrane-type receptor binds its agonist, it activates G proteins by cata-

lyzing the exchange of GDP for guanosine triphosphate (GTP) on the $G\alpha$ subunit. Subsequently, GTP-bound $G\alpha$ dissociates from $G\beta\gamma$, and each of the two complexes activates distinct downstream effectors.⁷ In mammals, $G\alpha$ subunits are divided into four classes: $G\alpha_{i/o}$, $G\alpha_{q/11}$, $G\alpha_s$, and $G\alpha_{12/13}$.⁷ $G\alpha_o$, encoded by *GNAO1* (MIM 139311), is extremely abundant in brain tissue, where it can constitute up to approximately 0.5% of membrane protein,⁸ suggesting important roles in brain function. In fact, mice lacking $G\alpha_o$ show multiple neurological abnormalities, including generalized tremor, occasional seizures, severe motor-control impairment, hyperalgesia, and behavioral abnormalities with early postnatal lethality.^{9,10}

In this study, de novo *GNAO1* mutations were identified in four epileptic-encephalopathy-affected individuals, three of whom were diagnosed with OS. In addition, two of the four individuals showed involuntary movements, suggesting that aberration of $G\alpha_o$ can cause multiple neurodevelopmental phenotypes.

¹Department of Human Genetics, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan; ²Department of Pediatrics, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan; ³Department of Neurophysiology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan; ⁴Department of Biochemistry, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan; ⁵Division of Neurology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan; ⁶Division of Neurology, Clinical Research Institute, Kanagawa Children's Medical Center, 2-138-4 Mutsukawa, Minami-ku, Yokohama 232-8555, Japan; ⁷Department of Pediatrics, Nagano Red Cross Hospital, 5-22-1 Wakasato, Nagano 380-8582, Japan; ⁸Department of Pediatrics, Epilepsy Center, Nishi-Niigata Chuo National Hospital, Niigata 950-2085, Japan

⁹These authors contributed equally to this work

¹⁰Present address: Department of Neurology, Gunma Children's Medical Center, 779 Shimohakoda Hokkitsu-machi, Shibukawa, Gunma 377-8577, Japan

*Correspondence: naomat@yokohama-cu.ac.jp (N.M.), hsaisu@yokohama-cu.ac.jp (H.S.)

http://dx.doi.org/10.1016/j.ajhg.2013.07.014. ©2013 by The American Society of Human Genetics. All rights reserved.

Subjects and Methods

Subjects

Twelve individuals with OS were previously analyzed by whole-exome sequencing (WES).^{3,11} In addition, we analyzed parental samples from 5 of the 12 individuals by WES. Screening for *GNAO1* mutations was performed in 367 individuals with epileptic encephalopathy (including 62 OS cases) by high-resolution-melting (HRM) analysis (339 cases) and/or WES (100 cases). The diagnosis was made on the basis of clinical features and characteristic patterns on EEG. Experimental protocols were approved by the institutional review board of Yokohama City University School of Medicine and Yamagata University Faculty of Medicine. Informed consent was obtained from the families of all individuals.

DNA Samples

Genomic DNA was obtained from peripheral-blood leukocytes by standard methods. For detection of a mosaic mutation in individual 2, genomic DNA from saliva and nails was isolated with an Oragene DNA kit (DNA Genotek) and an ISOHAIR kit (Nippon Gene), respectively.

WES

Genomic DNA was captured with the SureSelect Human All Exon v.4 Kit (Agilent Technologies) and sequenced with four samples per lane on an Illumina HiSeq 2000 (Illumina) with 101 bp paired-end reads. Image analysis and base calling were performed by Sequencing Control Software with Real-Time Analysis and CASAVA software v.1.8 (Illumina). Exome data processing, variant calling, and variant annotation were performed as previously described.^{12–14} Reads were aligned to GRCh37 with Novoalign (Novocraft Technologies). Duplicate reads were removed with Picard, and local realignments around indels and base-quality-score recalibration were performed with the Genome Analysis Toolkit (GATK).¹³ Single-nucleotide variants and small indels were identified with the GATK UnifiedGenotyper and were filtered according to the Broad Institute's best-practice guidelines v.3. Not flagged as clinically associated, variants registered in dbSNP135 were filtered. Filter-passed variants were annotated with ANNOVAR.¹⁴ Pathogenic mutations detected by WES were confirmed by Sanger sequencing.

Mutation Screening

Genomic DNA was amplified with an illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare). Exons 1–8 covering the *GNAO1* coding region of two transcript variants (transcript variant 1, RefSeq accession number NM_020988.2, encoding $G\alpha_{o1}$; transcript variant 2, RefSeq accession number NM_138736.2, encoding $G\alpha_{o2}$) were screened by HRM analysis. The last two exons differ between the transcript variants. HRM analysis was performed with a Light Cycler 480 (Roche Diagnostics). Samples showing an aberrant melting curve in the HRM analysis were sequenced. PCR primers and conditions are shown in Table S1, available online. All mutations not present in publically available databases were verified with original genomic DNA and were searched for in the variant database of our 408 in-house control exomes.

Deep Sequencing of a Mosaic Mutation

PCR products (length 178 bp) spanning the c.521A>G mutation were amplified with the use of blood, saliva, and nail DNA samples

from individual 2 and blood DNA samples from her parents as a template. Adaptor ligation, nick repair, and amplification were performed with the Ion Xpress Plus Fragment Library Kit (Life Technologies) according to the manufacturer's protocol (part no. 4471989 Rev. B). Indexing was carried out with the Xpress Barcode Adapters 1–16 Kit (Life Technologies). Emulsion PCR and enrichment steps were carried out with the Ion OneTouch 200 Template Kit v.2 (Life Technologies) according to the manufacturer's protocol (part no. 4478371 Rev. A). Sequencing of the amplicon libraries was carried out on the Ion Torrent Personal Genome Machine (PGM) with the Ion 314 sequencing chip and the Ion PGM 200 Sequencing Kit (Life Technologies) according to the recommended protocol (part no. 4474246 Rev. B). Torrent Suite 2.2 was used for all analyses. The percentage of mosaicism was examined with the Integrative Genomics Viewer.^{15,16}

Expression Vectors

A full-length human *GNAO1* cDNA clone (transcript variant 1, encoding $G\alpha_{o1}$) was purchased from Kazusa DNA Research Institute. Human *GNAO1* cDNA was inserted into a pEF6/V5-His-C vector for the introduction of a C-terminal V5 epitope (Life Technologies). Site-directed mutagenesis using a KOD-Plus-Mutagenesis kit (Toyobo) was performed for generating *GNAO1* mutants, including c.521A>G (p.Asp174Gly), c.572_592del (p.The191_Phe197del), c.836T>A (p.Ile279Asn), and c.607G>A (p.Gly203Arg). A c.607_609delinsACA (p.Gly203Thr) mutant, in which GTP binding was reversible in contrast to the WT,¹⁷ was also generated to serve as the known loss-of-function mutant.¹⁸ All variant cDNAs were confirmed by Sanger sequencing.

Immunofluorescence Microscopy

Mouse neuroblastoma 2A (N2A) cells were grown as previously described.⁴ N2A cells on glass coverslips were transfected with 200 ng of plasmid DNA with the use of X-tremeGENE 9 DNA Transfection Reagent (Roche Diagnostics). After 24 hr, cells were fixed in PBS containing 4% paraformaldehyde for 15 min and permeabilized in PBS containing 0.1% Triton X-100 for 5 min. Cells were then blocked with 10% normal goat serum for 30 min. V5-tagged $G\alpha_{o1}$ was detected with a mouse V5 antibody (1:200 dilution; Life Technologies) and Alexa-488-conjugated goat anti-mouse IgG (1:1000 dilution; Life Technologies). Coverslips were mounted with Vectashield (Vector Laboratories) that contained DAPI and were visualized with an inverted FV1000-D confocal microscope (Olympus).

Structural Modeling and Free-Energy Calculations

We used FoldX software (version 3.0 β 5) to construct mutated molecular structures and calculate the free-energy changes caused by the mutations.¹⁹ We used crystal structures of the GDP-bound inactive $G\alpha_4\beta\gamma$ heterotrimer (Protein Data Bank [PDB] 1GG2),²⁰ the nucleotide-free $G\alpha_s\beta\gamma$ in complex with agonist-occupied monomeric β_2 adrenergic receptor (β_2AR) (PDB 3SN6),²¹ and the transition-state analog of GTP (GDP⁺AlF₄⁻)-bound $G\alpha_q$ in complex with its effector phospholipase C- β (PLC β) (PDB 3OHM)²² as three-dimensional structure models of the $G\alpha_o$ subunit in different complexed states. Each of the mutations, corresponding to p.Asp174Gly, p.Ile279Asn, or p.Gly203Arg in the human $G\alpha_o$ subunit, was introduced into the $G\alpha$ subunit of each complex, and the free-energy change upon the mutation was calculated with FoldX software. Note that ligands included in the complexes were ignored in the calculation because the FoldX energy function




Figure 1. De Novo *GNAO1* Mutations in Individuals with Epileptic Encephalopathy
Schematic representation of *GNAO1*, including two transcript variants: transcript variant 1 (RefSeq NM_020988.2) with nine exons and transcript variant 2 (RefSeq NM_138736.2) with eight exons. The UTRs and coding regions are shown in white and black rectangles, respectively. Three mutations occurred in common exons of two transcript variants, and one mutation occurred uniquely in transcript variant 1. Note that the electropherogram of individual 2 suggested mosaicism of the c.521A>G mutation, and a heterozygous C>T change (rs1065375) was clearly demonstrated. All mutations caused substitution or deletion of evolutionarily conserved amino acids. Homologous sequences were aligned with the use of the CLUSTALW web site.

does not consider the contribution of ligands. The calculation was repeated three times, and the resultant data were presented as an average value with a SD.

Electrophysiology

For electrophysiological recording of calcium currents, we used NG108-15 cells transfected with individual *GNAO1* mutants. Expression vectors were introduced by electroporation with the Lonza Nucleofector device and the Cell Line Nucleofector Kit V (Lonza) according to the manufacturer's protocol (program X-023). Two micrograms of plasmid DNA was used per transfection. The transfected cells were plated on poly-L-lysine-coated plastic coverslips (Cell Desk LF, MS-0113L; Sumitomo Bakelite) at a density of about 5×10^4 cells/cm² and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). One day after transfection, the cells were differentiated with DMEM supplemented with 10 μ M prostaglandin E1, 50 μ M IBMX, and 1% FBS for 3–7 days before recording. During the culture period, half of the medium was changed every other day.

The recording was made by the perforated whole-cell patch-clamp technique with amphotericin B. Cells on coverslips were perfused under an Olympus BX51W upright microscope (Olympus) with a bath solution containing 140 mM NaCl, 5 mM CaCl₂, 4 mM KCl, 1 mM MgCl₂, 10 mM HEPES, 10 mM TEACl, 8 mM glucose, and 0.0002 mM tetrodotoxin (pH 7.3 adjusted with NaOH). The patch pipette solution contained 100 mM CsCl, 10 mM EGTA, and 40 mM HEPES (pH 7.3 adjusted with CsOH). Amphotericin B was added to the pipette solution at 2 μ l/ml just before the experiments. The pipettes were fabricated from borosilicate glass capillaries and had a resistance of 4–8 M Ω when backfilled with the amphotericin-B-containing pipette solution. The recording was started when the series resistance was reduced to <150 M Ω after gigaseal formation and clear cellular capacitive surges had appeared. Voltage-gated calcium currents were elicited by the application of 50 ms depolarizing pulses to +10 mV from the holding potential of –65 mV, recorded with a Multiclamp 700B (Molecular Devices) controlled via

pCLAMP10 software (Molecular Devices), filtered at 2 kHz, and sampled at 10 kHz with 50% compensation for series resistance.

G_{α_o} -mediated current inhibition was elicited by the application of 10 μ M norepinephrine via the bath solution. After 3–5 min, inhibition was assessed by measurement of the changes in current density just before the end of the depolarizing pulses. Recordings were made at room temperature.

Statistical multiple comparisons were made with ANOVA followed by Dunnett's post hoc test, and the threshold p value for judging statistical significance was 0.05. The current inhibition induced by norepinephrine in individual mutant-expressing cells was assessed with a paired t test. The results are given as the mean \pm SEM.

Results

GNAO1 Is Mutated in Individuals with Epileptic Encephalopathy

We previously performed WES of 12 individuals with OS.^{3,11} In this study, we analyzed parental samples from 5 of the 12 individuals by WES (mean RefSeq read depth of 109) to systematically screen de novo or recessive mutations. We found no recessive mutations in *SLC25A22* (MIM 609302), *PNPO* (MIM 610090), *PNKP* (MIM 613402), *PLCB1* (MIM 613722), or *ST3GAL3* (MIM 615006), whose mutations were previously found in epileptic encephalopathy,^{23–27} but we did find one or two de novo mutations in each of the five trio exomes. Among them, a de novo missense mutation (c.836T>A [p.Ile279Asn]) in *GNAO1* at 16q12.2 was identified in individual 1. In the exome data of the other seven original individuals, we also found in individual 2 a second missense mutation (c.521A>G [p.Asp174Gly]), which was confirmed as a de novo event by Sanger sequencing (Figure 1). Moreover, *GNAO1* mutation screening in 367 individuals with epileptic encephalopathy by HRM analysis (339 individuals) and/or WES (100 individuals,

Table 1. Clinical Features of Individuals with a *GNAO1* Mutation

	Individual 1	Individual 2	Individual 3	Individual 4
Gender	female	female	female	female
Age	13 years	4 years, 1 month	died at 11 months	8 years
Mutation	c.836T>A (p.Ile279Asn)	c.521A>G (p.Asp174Gly)	c.572_592 del (p.Thr191_Phe197 del)	c.607G>A (p.Gly203Arg)
Inheritance	de novo	de novo, somatic mosaic	de novo	de novo
Diagnosis	Ohtahara syndrome	Ohtahara syndrome	Ohtahara syndrome	epileptic encephalopathy
Initial symptom	tonic seizure at 4 days	series of tonic seizures at 29 days (tonic upgaze, head nodding, extension of all extremities)	series of tonic seizures at 2 weeks (resemble spasms)	opisthotonic posture, developmental delay at 7 months
Initial EEG	suppression-burst pattern at 4 days	suppression-burst pattern at 29 days	suppression-burst pattern at 2 weeks	diffuse irregular spike-and-slow-wave complex at 5 years
Course of seizures	tonic seizure at 5 years	series of tonic seizures at 9 months	tonic seizure at 10 months	focal seizure (tonic upgaze), tonic seizure at 5 years
Course of EEG	multifocal sharp waves at 1 year, 4 months; suppression-burst pattern at 5 years, 6 months	hypsarrhythmia at 3 months; diffuse spike-and-slow-wave complex at 1 year, 7 months; sharp waves at frontal lobe at 3 years, 9 months	hypsarrhythmia at 4 months	not done
Involuntary movement	-	-	dystonia	severe chorea, athetosis
Seizure control	intractable (2–3 times per day)	intractable (0–2 times per day)	intractable	intractable (several times per day)
Development				
Head control	-	+	-	-
Sitting	-	-	-	-
Meaningful words	-	-	-	-
MRI	normal at 1 month; cerebral atrophy at 5 years, 6 months	delayed myelination and thin corpus callosum at 10 months	normal at 3 months	delayed myelination at 1 year, 3 months; reduced cerebral white matter, thin corpus callosum at 4 years, 8 months

mean read depth of 129) revealed two de novo mutations: c.572_592 del (p.Thr191_Phe197del) in individual 3 and c.607G>A (p.Gly203Arg) in individual 4 (Figure 1). One mutation (c.836T>A) specifically affects *GNAO1* transcript variant 1, whereas the other three mutations affect both transcript variants 1 and 2. Web-based prediction tools suggested that these four mutations would be pathogenic (Table S2). None of the four mutations was found in the 6,500 exomes of the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project Exome Variant Server or among our 408 in-house control exomes. Interestingly, exome data and Sanger sequencing indicated that the c.521A>G mutation in individual 2 was somatic mosaic (Figure 1 and Table S3). We confirmed de novo somatic mosaicism of the c.521A>G mutation by deep sequencing of PCR products amplified with blood, nail, and saliva DNA from individual 2 and blood DNA from her parents, showing that approximately 35%–50% of cells harbored the mutation (Table S3).

Phenotypes Associated with *GNAO1* Mutations

Neurological features of four female individuals with *GNAO1* mutations are shown in Table 1. Three individuals (individuals 1–3) developed tonic seizures with suppression-burst pattern on EEG at the onset (range 4–29 days), leading to a diagnosis of OS. Individuals 2 and 3 transitioned to West syndrome, a common infantile epileptic syndrome, as revealed by hypsarrhythmia on EEG at 3–4 months of age (Figures 2A–2C). Individual 4 showed developmental delay and opisthotonic posture at 7 months of age, and complex partial seizures with epileptic discharge on EEG was observed at 5 years (Figure 2D). Of note, two individuals showed involuntary movements: individual 3 showed dystonia, and individual 4 displayed chorea and athetosis (Table 1 and Movie S1). Brain MRI showed delayed myelination in individuals 2 and 4, cerebral atrophy or reduced cerebral white matter in individuals 1 and 4, and thin corpus callosum in individuals 2 and 4 (Figures 2E–2I). Although seizures and EEG




Figure 2. EEG and Brain MRI Features of Individuals with *GNAO1* Mutations

(A and B) Interictal EEG of individual 3. A suppression-burst pattern was observed at 2 months of age (A), and transition to hypsarrhythmia was observed at 4 months (B).

(C) Interictal EEG of individual 2 shows a suppression-burst pattern at 2 months.

(D) Interictal EEG of individual 4 shows a diffuse spike- or sharp-and-slow-wave complex at 5 years.

(E–I) T2-weighted axial images through the basal ganglia (E, H, and I) and T1-weighted axial (F) and sagittal (G) images. Individual 1 showed cerebral atrophy at 5 years and 6 months (E). Individual 2 showed delayed myelination and thin corpus callosum at 10 months (F and G). Individual 3 showed normal appearance at 3 months (H). Individual 4 showed reduced white matter at 7 years (I).

findings in two individuals with OS (individuals 2 and 3) were temporarily improved by adrenocorticotropic hormone therapy and valproic acid, all four individuals had intractable epileptic seizures in spite of combinatory therapy of antiepileptic drugs. All individuals had severe intellectual disability and motor developmental delay, and individual 3 died at 11 months because of respiratory-tract obstruction. These data suggest that *GNAO1* mutations can cause multiple neurodevelopmental phenotypes, including epileptic encephalopathy and involuntary movements.

Expression of Mutant $G\alpha_{o1}$ in N2A Cells

To examine the mutational effect of four *GNAO1* mutations, we performed transient expression experiments in N2A cells (Figure 3). C-terminally V5-epitope-tagged wild-type (WT) $G\alpha_{o1}$, encoded by transcript variant 1, was clearly localized in the cell periphery, as previously reported.²⁸ The p.Gly203Thr (with known loss of function)¹⁷ and p.Gly203Arg (in individual 4) altered proteins were also localized in the cell periphery. In contrast, the p.Thr191_Phe197del altered protein (in individual 3) accumulated in the cytosolic compartment. The p.Asp174Gly




Figure 3. Localization of V5-Tagged $G\alpha_{o1}$ Proteins in N2A Cells
 Localization of WT and five altered $G\alpha_{o1}$ proteins in N2A cells. The WT and p.Gly203Arg and p.Gly203Thr altered proteins were localized to the cell periphery. In contrast, the p.Thr191_Phe197del protein was localized to the cytosolic compartment. The other p.Asp174Gly and p.Ile279Asn proteins were localized to the cell periphery but were also observed in the cytosol. The scale bars represent 10 μ m.

(individual 2) and p.Ile279Asn (individual 1) altered proteins were localized to the cell periphery and had weak signal in the cytosol, where more intense signal was observed in the p.Asp174Gly protein. Similar patterns of localization were observed for C-terminally AcGFP1-tagged $G\alpha_{o1}$ (Figure S1). These localization patterns suggest that the function of the p.Thr191_Phe197del altered protein might be most severely affected.

Structural Impacts of the Mutations on the $G\alpha$ -Containing Complexes

To evaluate the impact of the *GNAO1* mutations on specific functions at the atomic level, we mapped the substituted positions onto structures of the $G\alpha$ subunit in

complexed states representing the GDP-bound inactive state, the nucleotide-free $G\alpha_s\beta\gamma$ in complex with the receptor, and the GTP-bound active state. In the case of point mutations, we further estimated free-energy changes of the mutations by using FoldX software (version 3.0 β 5).¹⁹

The region corresponding to amino acid residues 191–197 of human $G\alpha_{o1}$ is located in β strands and their connecting loop region and is involved in interactions with the G-protein-coupled receptor (GPCR) in the $G\alpha\beta\gamma$ - β 2AR complex (Figure 4A and Figure S2A). Thus, the deletion would affect secondary structure of the molecule and would not only impair the interaction with GPCR but also severely destabilize the $G\alpha$ -subunit fold. The substituted residues corresponding to Asp174 and Ile279 of the human $G\alpha_{o1}$ subunit are both buried inside the protein (Figure 4A) and are involved in hydrogen-bonding and hydrophobic interactions, respectively (Figure S2B). Therefore, the p.Asp174Gly and p.Ile279Asn substitutions would destabilize the $G\alpha$ -subunit fold, as supported by FoldX calculations showing a more than 2 kcal/mol increase in free-energy changes for these substitutions (Figure 4B). It can be speculated that these altered proteins tend to be misfolded or denatured in N2A cells and thus have altered cellular localization (Figure 3).

The substituted residue corresponding to Gly203 of human $G\alpha_{o1}$ is located within the highly conserved switch II region, responsible for activation of downstream effectors upon GTP binding (Figure 4A). Conformations of the switch regions differ depending on the complex state of the G protein. In the $G\alpha\beta\gamma$ heterotrimer and the GDP⁺AlF₄⁻-bound $G\alpha$ -effector (PLC β) complex, the glycine residues are closely surrounded by the switch I region and GTP (Figure 4A and Figure S2C). Thus, the p.Gly203Arg substitution would cause steric hindrance between the arginine side chain and the switch I region and/or GTP, destabilizing the complex, as supported by the FoldX calculations showing a remarkable increase in free-energy change upon the p.Gly203Arg substitution. By contrast, in the $G\alpha\beta\gamma$ -receptor (β 2AR) complex, no substantial steric hindrance was predicted from the structural modeling and FoldX calculations (Figure 4B and Figure S2C). These findings suggest that the p.Gly203Arg-substituted $G\alpha$ subunit would impair GTP binding and/or activation of the downstream effectors, although it might still bind to GPCR. This prediction was supported by previous reports, in which GTP binding was weakened in the p.Gly203Thr altered $G\alpha$.¹⁷ This also appears to be consistent with the apparently normal cellular localization of the p.Gly203Arg altered protein in N2A cells (Figure 3).

Electrophysiological Evaluation of $G\alpha_{o1}$ Mutants

It has been reported that N-type calcium channels are inhibited, at least in part, via $G\alpha_o$ -mediated signaling.⁷ Using NG108-15 cells, in which norepinephrine-induced calcium-current inhibition is mediated by $G\alpha_o$ (Figure 5A),²⁹ we analyzed functional properties of altered $G\alpha_{o1}$. Compared with cells expressing WT $G\alpha_{o1}$ (the




Figure 4. Structural Consideration of the $G\alpha$ Amino Acid Substitutions in Some Complexed States

(A) Map of the amino acid substitution sites on the crystal structures of $G\alpha$ -containing complexes: the GDP-bound inactive $G\alpha\beta\gamma$ heterotrimer (left), the nucleotide-free $G\alpha\beta\gamma$ in complex with an agonist-occupied monomeric $\beta 2AR$ (center), and the $GDP+AlF_4$ -bound $G\alpha_q$ in complex with its effector PLC β (right). Molecular structures are shown as space-filling representations (from PyMOL). $G\alpha$, $G\beta$, and $G\gamma$ subunits are colored green, yellow, and pink, respectively, and the switch I and switch II regions in the $G\alpha$ subunit are in light green. The $\beta 2AR$ (center) and PLC β (right) molecules are colored brown. The substituted sites are shown in red, and the indicated amino acid numbers correspond to human $G\alpha_{o1}$ and, in parentheses, rat $G\alpha_{i1}$ (UniProtKB/Swiss-Prot P10824) (left), bovine $G\alpha_s$ (UniProtKB/Swiss-Prot P04896) (center), and mouse $G\alpha_q$ (UniProtKB/Swiss-Prot P21279) (right). The illustrations above each model show the orientation of each subunit and the bound molecules.

(B) The free-energy change after each of the amino acid substitutions was estimated from calculations using FoldX software. Each error bar represents an average value with a SD.

leftmost column in Figure 5B), NG108-15 cells expressing the p.Thr191_Phe197del substitution revealed a significant increase in calcium-current density before application of norepinephrine ($p < 0.05$ by Dunnett's post hoc test; the second column from the right in Figure 5B), suggesting that localization of the altered $G\alpha_{o1}$ might affect calcium-channel activity. In cells expressing the p.Asp174Gly substitution, a mild increase in the current density was also suggested, although the difference was not significant (the third column from the left in Figure 5B). The other two substitutions had no effects on the current (the second column from the left and the rightmost column in Figure 5B). Treatment with 10 μM norepinephrine reduced the calcium-current density by $19.0\% \pm 5.0\%$ in cells expressing WT $G\alpha_{o1}$ ($p < 0.01$ by paired t test; left panel in Figure 5A and the leftmost bar in Figure 5C). A similar reduction was observed in cells expressing the p.Ile279Asn alteration ($18.5\% \pm 3.5\%$, $p < 0.01$ by paired t test; the rightmost bar in Figure 5C). In cells expressing the p.Thr191_Phe197del alteration, by contrast, the reduction was obscured ($12.1\% \pm 5.0\%$, not significant by paired t test; right panel in Figure 5A and the second bar from the right in Figure 5C). In cells expressing the other two substitutions (p.Gly203Thr and p.Asp174Gly), weaker current inhibition by norepinephrine was suggested ($9.9\% \pm 3.8\%$ and $11.1\% \pm 3.5\%$, respectively; both were $p < 0.05$ by paired t test; the second and third bars from the left in Figure 5C), although compared with that in WT-expressing cells, the degrees

of inhibition in Gly203Thr- and p.Asp174Gly-expressing cells did not reach statistical significance (not significant by ANOVA). These data suggest that $GNAO1$ mutations could hamper $G\alpha_o$ -mediated signaling.

Discussion

We successfully identified four de novo heterozygous missense $GNAO1$ mutations in four individuals. All four individuals showed severe intellectual disability and motor developmental delay, demonstrating that aberration of $G\alpha_o$ affects intellectual and motor development. In addition, all four individuals showed epileptic encephalopathy, and two of them showed involuntary movements. Because $G\alpha_o$ -deficient mice show occasional seizures and generalized tremor,^{9,10} it is likely that epilepsy and involuntary movement are two of the characteristic features caused by $GNAO1$ mutations. Although $G\alpha_o$ -deficient mice also show hyperactivity and hyperalgesia,¹⁰ it is difficult to evaluate whether our individuals had these symptoms because of severe motor and cognitive impairment.

All four of these mutations, and especially two mutations leading to the p.Thr191_Phe197del and p.Gly203Arg substitutions, are predicted to affect $G\alpha_o$ function by structural evaluation. In fact, transient expression in N2A cells showed that localization of the p.Thr191_Phe197del altered protein was dramatically changed to the cytosolic compartment. Interestingly, two alterations (p.Ile279Asn




Figure 5. Evaluation of $G\alpha_o$ -Mediated Signaling in NG108-15 Cell Calcium-Current Generation

(A) Representative traces of voltage-gated calcium currents generated in NG108-15 cells expressing WT (left) or p.Thr191_Phe197del altered (right) $G\alpha_{o1}$. Black and red traces represent the currents before and 3 min after application of 10 μ M norepinephrine, respectively.

(B) Current densities of the calcium currents before norepinephrine treatment in cells expressing WT or altered $G\alpha_{o1}$. Scatter plots represent the densities in individual cells. Red squares and bars represent the means and SEMs, respectively, of the densities in individual cell groups (WT, $n = 8$; p.Gly203Thr, $n = 7$; p.Asp174Gly, $n = 8$; p.Thr191_Phe197del, $n = 7$; p.Ile279Asn, $n = 7$). Compared with that in cells expressing WT $G\alpha_{o1}$, the current density in cells expressing p.Thr191_Phe197del increased significantly ($*p < 0.05$ by Dunnett's post hoc test). The densities in the cells expressing other altered proteins did not vary significantly.

(C) Comparison of norepinephrine-induced inhibition of calcium currents in cells expressing altered $G\alpha_{o1}$. Each error bar represents the mean and SEM of the percent decrease in current density

induced by application of 10 μ M norepinephrine. Paired t tests indicated that the inhibition induced by norepinephrine was significant in cells expressing WT ($n = 8$) and p.Gly203Thr ($n = 7$), p.Asp174Gly ($n = 8$), and p.Ile279Asn ($n = 7$) altered proteins (** $p < 0.01$ and $*p < 0.05$), but not in cells expressing p.Thr191_Phe197del ($n = 7$). Although there was some tendency for decreased inhibition in cells expressing altered proteins, the tendency did not reach statistical significance compared with that in WT-expressing cells ($p = 0.41$ by ANOVA).

and p.Asp174Gly) also showed weak signal in the cytosol, suggesting that localization to the plasma membrane was variably impaired in three altered proteins. Measurement of voltage-dependent calcium currents in NG108-15 cells also suggested impaired functions of altered $G\alpha_{o1}$. The p.Thr191_Phe197del alteration significantly increased the basal calcium-current density, and compared with WT-expressing cells, cells expressing one of the three substitutions (p.Thr191_Phe197del, p.Asp174Gly, or p.Gly203Thr) showed a tendency towards weaker inhibition of calcium currents by norepinephrine. All these data suggest that the four *GNAO1* mutations might cause loss of $G\alpha_{o1}$ function.

Our experimental data suggest that $G\alpha_o$ function might be most severely affected in the p.Thr191_Phe197del altered protein. This appears to be correlated with the severity of clinical features because individual 3 showed both OS and involuntary movements and indeed died during the infantile period. Therefore, she might have had the most severe phenotype caused by a *GNAO1* mutation. Another interesting finding is somatic mosaicism of the c.521A>G (p.Asp174Gly) mutation in individual 2, in whom approximately 35%–50% of cells harbored the mutation. Somatic mosaicism of responsive genes in infantile epilepsy, such as *SCN1A* (MIM 182389) and *STXBP1*, have been reported, explaining the presence of unaffected

or mildly affected transmitting parents.^{30,31} However, individual 2 showed OS, delayed myelination, and thin corpus callosum. Although we did not determine the mosaic rate in brain tissues, the presence of 35%–50% of cells harboring the *GNAO1* mutation in the brain might be sufficient to cause abnormal brain development.

It has been reported that activation of G-protein-coupled α_2 adrenergic receptors by norepinephrine attenuates epileptiform activity in the hippocampal CA3 region.³² $G\alpha_o$ is known to be involved in this response,³³ suggesting that alteration of pathways mediated by α_2 adrenergic receptor and $G\alpha_o$ might contribute to the pathogenesis of epilepsy. Because calcium-current inhibition is a well-known consequence of $G\alpha_o$ -mediated signaling induced by norepinephrine, it is possible that epileptic seizures associated with *GNAO1* mutations might be improved by calcium-channel modulators. For example, pregabalin and gabapentin act as selective calcium-channel blockers,^{34,35} and topiramate modulates high-voltage-activated calcium channels in dentate granule cells.³⁶ Because our four individuals were not treated with these drugs, it is worth administering these three drugs for examining putative protective effects.

In conclusion, de novo heterozygous *GNAO1* mutations were identified in four individuals with epileptic encephalopathy. Furthering our understanding of abnormal

G α_o -mediated heterotrimeric G protein signaling might provide new insights into the pathogenesis and treatment of epileptic encephalopathy.

Supplemental Data

Supplemental Data include two figures, three tables, and one movie and can be found with this article online at <http://www.cell.com/AJHG>.

Acknowledgments

We would like to thank the individuals and their families for their participation in this study. We also thank Aya Narita and Nobuko Watanabe for their technical assistance and Tohru Kozasa and Nobuchika Suzuki for their valuable comments. This work was supported by the Ministry of Health, Labour, and Welfare of Japan, the Japan Society for the Promotion of Science (Grants-in-Aid for Scientific Research (B) [25293085 and 25293235] and a Grant-in-Aid for Scientific Research (A) [13313587]), the Takeda Science Foundation, the Japan Science and Technology Agency, the Strategic Research Program for Brain Sciences (11105137), and a Grant-in-Aid for Scientific Research on Innovative Areas (Transcription Cycle) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (12024421).

Received: May 17, 2013

Revised: July 9, 2013

Accepted: July 17, 2013

Published: August 29, 2013

Web Resources

The URLs for data presented herein are as follows:

CLUSTALW, <http://www.genome.jp/tools/clustalw/>
GenBank, <http://www.ncbi.nlm.nih.gov/Genbank/>
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, <http://evs.gs.washington.edu/EVS/>
Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org/>
Picard, <http://picard.sourceforge.net/>
Protein Data Bank, <http://www.rcsb.org/pdb/home/home.do>
PyMOL, www.pymol.org
RefSeq, <http://www.ncbi.nlm.nih.gov/RefSeq>
UniProtKB/Swiss-Prot, <http://www.uniprot.org/>

References

- Dulac, O. (2001). Epileptic encephalopathy. *Epilepsia* 42 (Suppl 3), 23–26.
- Ohtahara, S., and Yamatogi, Y. (2006). Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy. *Epilepsy Res.* 70 (Suppl 1), S58–S67.
- Saito, H., Kato, M., Koide, A., Goto, T., Fujita, T., Nishiyama, K., Tsurusaki, Y., Doi, H., Miyake, N., Hayasaka, K., and Matsumoto, N. (2012). Whole exome sequencing identifies *KCNQ2* mutations in Ohtahara syndrome. *Ann. Neurol.* 72, 298–300.
- Saito, H., Kato, M., Mizuguchi, T., Hamada, K., Osaka, H., Tohyama, J., Uruno, K., Kumada, S., Nishiyama, K., Nishimura, A., et al. (2008). *De novo* mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. *Nat. Genet.* 40, 782–788.
- Weckhuysen, S., Mandelstam, S., Suls, A., Audenaert, D., Deconinck, T., Claes, L.R., Deprez, L., Smets, K., Hristova, D., Yordanova, I., et al. (2012). *KCNQ2* encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. *Ann. Neurol.* 71, 15–25.
- Kato, M., Saito, S., Kamei, A., Shiraishi, H., Ueda, Y., Akasaka, M., Tohyama, J., Akasaka, N., and Hayasaka, K. (2007). A longer polyalanine expansion mutation in the *ARX* gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). *Am. J. Hum. Genet.* 81, 361–366.
- Wettschreck, N., and Offermanns, S. (2005). Mammalian G proteins and their cell type specific functions. *Physiol. Rev.* 85, 1159–1204.
- Huff, R.M., Axton, J.M., and Neer, E.J. (1985). Physical and immunological characterization of a guanine nucleotide-binding protein purified from bovine cerebral cortex. *J. Biol. Chem.* 260, 10864–10871.
- Valenzuela, D., Han, X., Mende, U., Fankhauser, C., Mashimo, H., Huang, P., Pfeffer, J., Neer, E.J., and Fishman, M.C. (1997). G α_o is necessary for muscarinic regulation of Ca $^{2+}$ channels in mouse heart. *Proc. Natl. Acad. Sci. USA* 94, 1727–1732.
- Jiang, M., Gold, M.S., Boulay, G., Spicher, K., Peyton, M., Brabet, P., Srinivasan, Y., Rudolph, U., Ellison, G., and Birnbaumer, L. (1998). Multiple neurological abnormalities in mice deficient in the G protein Go. *Proc. Natl. Acad. Sci. USA* 95, 3269–3274.
- Saito, H., Kato, M., Osaka, H., Moriyama, N., Horita, H., Nishiyama, K., Yoneda, Y., Kondo, Y., Tsurusaki, Y., Doi, H., et al. (2012). *CASK* aberrations in male patients with Ohtahara syndrome and cerebellar hypoplasia. *Epilepsia* 53, 1441–1449.
- Saito, H., Nishimura, T., Muramatsu, K., Kodaera, H., Kumada, S., Sugai, K., Kasai-Yoshida, E., Sawaura, N., Nishida, H., Hoshino, A., et al. (2013). *De novo* mutations in the autophagy gene *WDR45* cause static encephalopathy of childhood with neurodegeneration in adulthood. *Nat. Genet.* 45, 445–449, e1.
- DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C., Philippakis, A.A., del Angel, G., Rivas, M.A., Hanna, M., et al. (2011). A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat. Genet.* 43, 491–498.
- Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 38, e164.
- Robinson, J.T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G., and Mesirov, J.P. (2011). Integrative genomics viewer. *Nat. Biotechnol.* 29, 24–26.
- Thorvaldsdóttir, H., Robinson, J.T., and Mesirov, J.P. (2013). Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief. Bioinform.* 14, 178–192.
- Slepak, V.Z., Wilkie, T.M., and Simon, M.I. (1993). Mutational analysis of G protein alpha subunit G(o) alpha expressed in *Escherichia coli*. *J. Biol. Chem.* 268, 1414–1423.
- Williams, D.J., Puhl, H.L., and Ikeda, S.R. (2010). A Simple, Highly Efficient Method for Heterologous Expression in Mammalian Primary Neurons Using Cationic Lipid-mediated mRNA Transfection. *Front Neurosci.* 4, 181.

19. Guerois, R., Nielsen, J.E., and Serrano, L. (2002). Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. *J. Mol. Biol.* **320**, 369–387.
20. Wall, M.A., Coleman, D.E., Lee, E., Iñiguez-Lluhi, J.A., Posner, B.A., Gilman, A.G., and Sprang, S.R. (1995). The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2. *Cell* **83**, 1047–1058.
21. Rasmussen, S.G., DeVree, B.T., Zou, Y., Kruse, A.C., Chung, K.Y., Kobilka, T.S., Thian, F.S., Chae, P.S., Pardon, E., Calinski, D., et al. (2011). Crystal structure of the $\beta 2$ adrenergic receptor-Gs protein complex. *Nature* **477**, 549–555.
22. Waldo, G.L., Ricks, T.K., Hicks, S.N., Cheever, M.L., Kawano, T., Tsuboi, K., Wang, X., Montell, C., Kozasa, T., Sondek, J., and Harden, T.K. (2010). Kinetic scaffolding mediated by a phospholipase C-beta and Gq signaling complex. *Science* **330**, 974–980.
23. Edvardson, S., Baumann, A.M., Mühlenhoff, M., Stephan, O., Kuss, A.W., Shaag, A., He, L., Zenvirt, S., Tanzi, R., Gerardy-Schahn, R., and Elpeleg, O. (2013). West syndrome caused by ST3Gal-III deficiency. *Epilepsia* **54**, e24–e27.
24. Molinari, F., Raas-Rothschild, A., Rio, M., Fiermonte, G., Encha-Razavi, F., Palmieri, L., Palmieri, F., Ben-Neriah, Z., Kadhon, N., Vekemans, M., et al. (2005). Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. *Am. J. Hum. Genet.* **76**, 334–339.
25. Mills, P.B., Surtees, R.A., Champion, M.P., Beesley, C.E., Dalton, N., Scambler, P.J., Heales, S.J., Briddon, A., Scheimberg, I., Hoffmann, G.F., et al. (2005). Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase. *Hum. Mol. Genet.* **14**, 1077–1086.
26. Shen, J., Gilmore, E.C., Marshall, C.A., Haddadin, M., Reynolds, J.J., Eyaid, W., Bodell, A., Barry, B., Gleason, D., Allen, K., et al. (2010). Mutations in PNKP cause microcephaly, seizures and defects in DNA repair. *Nat. Genet.* **42**, 245–249.
27. Kurian, M.A., Meyer, E., Vassallo, G., Morgan, N.V., Prakash, N., Pasha, S., Hai, N.A., Shuib, S., Rahman, F., Wassmer, E., et al. (2010). Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy. *Brain* **133**, 2964–2970.
28. Nakata, H., and Kozasa, T. (2005). Functional characterization of Galphao signaling through G protein-regulated inducer of neurite outgrowth 1. *Mol. Pharmacol.* **67**, 695–702.
29. McFadzean, I., Mullaney, I., Brown, D.A., and Milligan, G. (1989). Antibodies to the GTP binding protein, Go, antagonize noradrenaline-induced calcium current inhibition in NG108-15 hybrid cells. *Neuron* **3**, 177–182.
30. Saitsu, H., Hoshino, H., Kato, M., Nishiyama, K., Okada, I., Yoneda, Y., Tsurusaki, Y., Doi, H., Miyake, N., Kubota, M., et al. (2011). Paternal mosaicism of an *STXBP1* mutation in OS. *Clin. Genet.* **80**, 484–488.
31. Marini, C., Scheffer, I.E., Nabbout, R., Suls, A., De Jonghe, P., Zara, F., and Guerrini, R. (2011). The genetics of Dravet syndrome. *Epilepsia* **52** (Suppl 2), 24–29.
32. Jurgens, C.W., Hammad, H.M., Lichter, J.A., Boese, S.J., Nelson, B.W., Goldenstein, B.L., Davis, K.L., Xu, K., Hillman, K.L., Porter, J.E., and Doze, V.A. (2007). Alpha2A adrenergic receptor activation inhibits epileptiform activity in the rat hippocampal CA3 region. *Mol. Pharmacol.* **71**, 1572–1581.
33. Goldenstein, B.L., Nelson, B.W., Xu, K., Luger, E.J., Pribula, J.A., Wald, J.M., O'Shea, L.A., Weinschenker, D., Charbeneau, R.A., Huang, X., et al. (2009). Regulator of G protein signaling protein suppression of Galphao protein-mediated alpha2A adrenergic receptor inhibition of mouse hippocampal CA3 epileptiform activity. *Mol. Pharmacol.* **75**, 1222–1230.
34. Sills, G.J. (2006). The mechanisms of action of gabapentin and pregabalin. *Curr. Opin. Pharmacol.* **6**, 108–113.
35. Stefani, A., Spadoni, F., Giacomini, P., Lavaroni, F., and Bernardi, G. (2001). The effects of gabapentin on different ligand- and voltage-gated currents in isolated cortical neurons. *Epilepsy Res.* **43**, 239–248.
36. Zhang, X., Velumian, A.A., Jones, O.T., and Carlen, P.L. (2000). Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. *Epilepsia* **41** (Suppl 1), S52–S60.

De Novo Mutations in *SLC35A2* Encoding a UDP-Galactose Transporter Cause Early-Onset Epileptic Encephalopathy

Hirofumi Kodera,^{1†} Kazuyuki Nakamura,^{1,2†} Hitoshi Osaka,³ Yoshihiro Maegaki,⁴ Kazuhiro Haginoya,^{5,6} Shuji Mizumoto,⁷ Mitsuhiro Kato,² Nobuhiko Okamoto,⁸ Mizue Iai,³ Yukiko Kondo,¹ Kiyomi Nishiyama,¹ Yoshinori Tsurusaki,¹ Mitsuko Nakashima,¹ Noriko Miyake,¹ Kiyoshi Hayasaka,² Kazuyuki Sugahara,⁷ Isao Yuasa,⁹ Yoshinao Wada,¹⁰ Naomichi Matsumoto,^{1*} and Hiroto Saito^{1**}

¹Department of Human Genetics, Yokohama City University Graduate School of Medicine, Kanazawa-ku, Yokohama 236-0004, Japan; ²Department of Pediatrics, Yamagata University School of Medicine, Yamagata 990-9585, Japan; ³Division of Neurology, Clinical Research Institute, Kanagawa Children's Medical Center, Minami-ku, Yokohama 232-8555, Japan; ⁴Division of Child Neurology, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan; ⁵Department of Pediatrics, Tohoku University School of Medicine, Aoba-ku, Sendai 980-8574, Japan; ⁶Department of Pediatric Neurology, Takuto Rehabilitation Center for Children, Taihaku-ku, Sendai 982-0241, Japan; ⁷Laboratory of Proteoglycan Signaling and Therapeutics, Frontier Research Center for Post-Genomic Science and Technology, Graduate School of Life Science, Hokkaido University, Sapporo 001-0021, Japan; ⁸Department of Medical Genetics, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi, Osaka 594-1101, Japan; ⁹Division of Legal Medicine, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan; ¹⁰Department of Molecular Medicine, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi, Osaka 594-1101, Japan

Communicated by María-Jesús Sobrido

Received 16 May 2013; accepted revised manuscript 15 September 2013.

Published online 30 September 2013 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22446

ABSTRACT: Early-onset epileptic encephalopathies (EOEE) are severe neurological disorders characterized by frequent seizures accompanied by developmental regression or retardation. Whole-exome sequencing of 12 patients together with five pairs of parents and subsequent Sanger sequencing in additional 328 EOEE patients identified two de novo frameshift and one missense mutations in *SLC35A2* at Xp11.23, respectively. The three patients are all females. X-inactivation analysis of blood leukocyte DNA and mRNA analysis using lymphoblastoid cells derived from two patients with a frameshift mutation indicated that only the wild-type *SLC35A2* allele was expressed in these cell types, at least in part likely as a consequence of skewed X-inactivation. *SLC35A2* encodes a UDP-galactose transporter (UGT), which selectively supplies UDP-galactose from the cytosol to the Golgi lumen. Transient expression experiments revealed that the mis-

sense mutant protein was correctly localized in the Golgi apparatus. In contrast, the two frameshift mutant proteins were not properly expressed, suggesting that their function is severely impaired. Defects in the UGT can cause congenital disorders of glycosylation. Of note, no abnormalities of glycosylation were observed in three serum glycoproteins, which is consistent with favorably skewed X-inactivation. We hypothesize that a substantial number of neurons might express the mutant *SLC35A2* allele and suffer from defective galactosylation, resulting in EOEE. Hum Mutat 34:1708–1714, 2013. © 2013 Wiley Periodicals, Inc.

KEY WORDS: early-onset epileptic encephalopathy; *SLC35A2*; congenital disorders of glycosylation

Additional Supporting Information may be found in the online version of this article.

†These authors contributed equally to this work.

*Correspondence to: Naomichi Matsumoto. Department of Human Genetics, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. E-mail: naomat@yokohama-cu.ac.jp

**Correspondence to: Hiroto Saito. Department of Human Genetics, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. E-mail: hsaito@yokohama-cu.ac.jp

Contract grant sponsors: Ministry of Health, Labour, and Welfare of Japan; the Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research B [25293085], [25293235], Grant-in-Aid for Scientific Research A [13313587]); Takeda Science Foundation; Japan Science and Technology Agency; Strategic Research Program for Brain Sciences (11105137); Grants-in-Aid for Scientific Research on Innovative Areas (Transcription Cycle, Neuroglycobiology) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (12024421, 24110501).

Introduction

Glycosylation is the process of adding complex sugar chains (glycans) to proteins and lipids. Protein glycosylation includes *N*-linked and *O*-linked glycosylation pathways in the endoplasmic reticulum (ER)–Golgi network [Freeze, 2013]. To enable glycan biosynthesis, monosaccharides in the form of nucleotide sugars, such as GDP-fucose, CMP-sialic acid, and UDP-galactose, must be delivered into the lumen of the ER and Golgi apparatus by their respective nucleotide-sugar transporters [Liu et al., 2010]. Defects of the glycosylation process cause congenital disorders of glycosylation (CDG). To date, nearly 70 CDG have been identified, most caused by either the *N*-linked or *O*-linked glycosylation pathway, or both [Freeze, 2013; Jaeken and Matthijs, 2007]. Because glycosylation is a ubiquitous cellular process, its defects affect multiple organ systems with various features, accompanied by facial dysmorphism. The central nervous system is one of the most often affected organs, frequently resulting in structural abnormalities, developmental delay, and epileptic seizures [Freeze et al., 2012].

Early-onset epileptic encephalopathies (EOEE), with onset before 1 year of age, are characterized by severe seizures (often), infantile spasms), frequent interictal epileptiform activity on a disorganized electroencephalogram (EEG) background, and developmental regression or retardation [Holland and Hallinan, 2010]. Ohtahara syndrome (MIMs # 308350, 612164), West syndrome (WS; MIMs # 308350, 300672, 612164), early myoclonic epileptic encephalopathy (MIM #609304), malignant migrating partial seizures of infancy (MIM #614959), and Dravet syndrome (MIM #607208) are the best known epileptic encephalopathies recognized by the International League Against Epilepsy. However, many infants with these syndromes do not strictly fit within the electroclinical parameters of these syndromes. Recently, several causative genes have been reported in patients both with well-recognized and unclassified EOEE syndromes: *ARX* (MIM #300382), *CDKL5* (MIM #300203), *STXBP1* (MIM #602926), *SLC25A22* (MIM #609302), *SCN1A* (MIM #182389), *KCNQ2* (MIM #602235), and *KCNT1* (MIM #608167) [Barcia et al., 2012; Claes et al., 2001; Kalscheuer et al., 2003; Kato et al., 2007; Molinari et al., 2005; Saitsu et al., 2008, 2012a; Stromme et al., 2002; Weckhuysen et al., 2012]. These genes encode sodium or potassium channels, transcription factors, a mitochondrial glutamate transporter, and a regulator of neurotransmitter release, and are able to explain part of the genetic cause of EOEE. Because epileptic seizures are one of the main symptoms with CDG, abnormal glycosylation may be found in EOEE. In fact, de novo mutations in *SLC35A2* (MIM #314375), encoding a UDP-galactose transporter (UGT), have recently been reported in three patients with CDG (one female with a heterozygous mutation and two males with a mosaic mutation), and two of them showed seizures and hypsarrhythmia on EEG, suggesting WS [Ng et al., 2013]. It would be worth checking *SLC35A2* mutations in a large cohort of patients with EOEE.

In this study, whole-exome sequencing (WES) of 12 patients together with five pairs of parents (five trios) and subsequent Sanger sequencing in additional 328 patients with EOEE identified two de novo frameshift and one de novo missense mutations in *SLC35A2*, respectively, confirming that de novo *SLC35A2* mutations are one of the genetic causes for EOEE.

Materials and Methods

Methods for RNA analysis, X-inactivation analysis, and mass spectrometry are described in the Supp. Methods.

Patients

A total of 328 patients with EOEE (67 patients with Ohtahara syndrome, 150 with WS, and 111 with unclassified EOEE) were analyzed for *SLC35A2* mutations. The diagnosis was made based on clinical features and characteristic patterns on EEG. In 257 patients, mutations in *STXBP1* and *KCNQ2* had been excluded by high-resolution melting analysis in advance. Experimental protocols were approved by the Institutional Review Board of Yokohama City University School of Medicine. Clinical information and peripheral blood samples were obtained from the family members after obtaining written informed consent.

Exome Sequencing

WES for 12 patients with EOEE, in whom initial diagnosis was Ohtahara syndrome, had been previously performed [Saitsu et al., 2012a, 2012b]. In this study, we additionally analyzed parental samples from five patients by WES. Genomic DNA was captured using

the SureSelectXT Human All Exon v4 Kit (Agilent Technologies, Santa Clara, CA) and sequenced with four samples per lane on an Illumina HiSeq 2000 (Illumina, San Diego, CA) with 101-bp paired-end reads. Image analysis and base calling were performed by sequence control software with real-time analysis and CASAVA software v1.8 (Illumina). Exome data processing, variant calling, and variant annotation were performed as previously described [DePristo et al., 2011; Saitsu et al., 2013; Wang et al., 2010]. All de novo candidate mutations detected by WES were confirmed by Sanger sequencing.

Mutation Screening

Genomic DNA was amplified using an illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare, Buckinghamshire, UK). Exons 1–5 covering the *SLC35A2* coding region of two transcript variants (transcript variant 1, GenBank accession number NM_005660.1, encoding UGT2; transcript variant 3, GenBank accession number NM_001042498.2, encoding UGT1) were screened by Sanger sequencing. PCR primers and conditions are available on request. All novel mutations were verified using original genomic DNA, and searched for in the variant database of our 408 in-house control exomes.

Expression Vectors

Total RNA from lymphoblastoid cells was reverse transcribed using the PrimeScript 1st strand synthesis kit with random hexamers (Takara, Ohtsu, Japan) as previously reported [Saitsu et al., 2010]. The following primers were used to isolate full-length human *SLC35A2* cDNA (amino acids 1–393, GenBank accession number NM_001042498.2): forward 5'-GGAATTCAGATGCCAACATGGCAGCGGTTGG-3' and reverse 5'-GGCTCGAGATTGCTGCCAGCCCTCACTTAC-3'. *SLC35A2* cDNA was inserted into pBlueScript SK(-) vector (Agilent Technologies), and site-directed mutagenesis was performed using a KOD-Plus-Mutagenesis kit (Toyobo, Osaka, Japan) according to the manufacturer's protocol to generate *SLC35A2* mutants including c.433_434del (p.Tyr145Profs*76), c.972del (p.Phe324Leufs*25), and c.638C>T (p.Ser213Phe). Subsequently, mutant *SLC35A2* cDNAs that excluded termination codons were amplified by PCR, inserted into pEF6/V5-His C vector (Life Technologies Co., Carlsbad, CA) to generate C terminal V5-epitope tag. All variant cDNAs were confirmed by Sanger sequencing.

Cell Culture

Mouse neuroblastoma 2A (N2A) cells were cultured at 37°C under 5% CO₂ in DMEM, high glucose, GlutaMAXTM supplemented with 10% fetal bovine serum and Penicillin–Streptomycin (Life Technologies Co.).

Immunofluorescence Microscopy

N2A cells on glass cover slips were transfected with 200 ng of plasmid DNA using X-tremeGENE 9 DNA Transfection Reagent (Roche Diagnostics, Mannheim, Germany). After 24 hr, cells were fixed in 4% paraformaldehyde/PBS for 15 min and permeabilized in 0.1% Triton X-100/PBS for 5 min. Cells were then blocked with 10% normal goat serum for 30 min. V5-tagged UGT1 were detected by mouse anti-V5 antibody (1:200 dilution; Life Technologies) and Alexa-488-conjugated goat anti-mouse immunoglobulin G (1:1000 dilution; Life Technologies). Cover slips were mounted using

Vectashield (Vector Laboratories, Youngstown, OH) that contained 4',6-diamidino-2-phenylindole (DAPI) and visualized with an inverted FV1000-D confocal microscope (Olympus, Tokyo, Japan).

Results

To systemically screen de novo or recessive mutations, we conducted trio-based WES in five patients with EOOE. None of the recessive mutations in known EOOE genes were found in WES data (*SLC25A22*, *PNPO*; MIM #610090, *PNKP*; MIM #613402, *PLCB1*; MIM #613722, and *ST3GAL3*; MIM #615006) [Hu et al., 2011; Kurian et al., 2010; Mills et al., 2005; Molinari et al., 2005; Shen et al., 2010]. Instead, we found one or two de novo nonsynonymous mutations in each of the five trios (Supp. Table S1). Among them, a sole de novo frameshift mutation in *SLC35A2* at Xp11.23 was found in two patients: c.433_434del (p.Tyr145Profs*76) in patient 1 and c.972del (p.Phe324Leufs*25) in patient 2, which were confirmed by Sanger sequencing. No *SLC35A2* mutation was found in the other seven patients analyzed by WES. However, subsequent *SLC35A2* mutation analysis by Sanger sequencing in a cohort of 328 patients with EOOE revealed another de novo missense mutation (c.638C>T [p.Ser213Phe]) in patient 3 (Fig. 1A). None of the three mutations was found in the 6,500 National Heart, Lung, and Blood Institute exomes (<http://evs.gs.washington.edu/EVS/>) or our 408 in-house control exomes. All patients with a *SLC35A2* mutation are female.

As human female cells are subject to X-chromosome inactivation, we examined the X-inactivation pattern using a fragile X mental retardation locus methylation assay and human androgen re-

ceptor assay on genomic DNA from peripheral leukocytes [Kondo et al., 2012]. A markedly skewed pattern was observed in patients 1 and 2 (noninformative in patient 3) (Supp. Table S2). Reverse-transcription PCR and sequencing of total RNA extracted from lymphoblastoid cell lines derived from patients 1 and 2 revealed that only the wild-type (WT) *SLC35A2* allele was expressed, suggesting that the mutant alleles underwent X-inactivation, though degradation of mutant transcripts by nonsense-mediated mRNA decay may be involved (Supp. Fig. S1). Cells from patient 3 were unavailable. It is unknown whether the mutant allele undergoes similar X-inactivation in brain tissues.

SLC35A2 encodes a UGT, which selectively supplies UDP-galactose from the cytosol to the Golgi lumen [Ishida et al., 1996; Miura et al., 1996]. Two human UGT splice variants have been studied: UGT1 encoded by transcript variant 3 (NM_001042498.2) and UGT2 by transcript variant 1 (NM_005660.1) [Ishida et al., 1996; Kabuss et al., 2005; Miura et al., 1996], both of which are predicted to have a 10-transmembrane domain and differ only at the carboxyl-terminal five or eight amino acid residues (Fig. 1B) [Kabuss et al., 2005; Miura et al., 1996]. The three mutations would affect both UGT1 and UGT2. Two mutations (p.Tyr145Profs*76 and p.Phe324Leufs*25) would cause truncation of UGT within the transmembrane domain, and the missense mutation (p.Ser213Phe) occurs at an evolutionarily conserved amino acid (Fig. 1B and Supp. Fig. S2). To examine the effect of the three *SLC35A2* mutations, we performed transient expression experiments in N2A cells. C-terminally V5 epitope-tagged WT UGT1 was localized to the Golgi apparatus, similar to endogenous UGT1 [Yoshioka et al., 1997]. The p.Ser213Phe mutant showed a similar expression pattern to




Figure 1. De novo *SLC35A2* mutations in EOOE patients. **A:** Schematic representation of *SLC35A2* (open and filled rectangles represent untranslated regions and coding regions, respectively). There are three transcript variants: variant 1 (GenBank accession number, NM_005660.1) encoding UGT2, variant 2 (NM_005660.1), and variant 3 (NM_001042498.2) encoding UGT1. The three de novo mutations occurred in both variants 1 and 3, but not in variant 2. **B:** Topological prediction of UGT1 and UGT2 proteins [Kabuss et al., 2005]. The three mutations (stars) are predicted to be localized in the transmembrane domains. The C-terminal five amino acids (SVLVK) in UGT1 are replaced by eight amino acids (LLTKVKGS) in UGT2. *SLC35A2* variants were deposited in a gene-specific database (<http://databases.lovd.nl/shared/genes/SLC35A2>).




Figure 2. Expression of V5-tagged UGT1 proteins in N2A cells. Expression of WT and the three mutant UGT1 proteins in N2A cells. V5-tagged WT UGT1 (top, green) and the p.Ser213Phe mutant (bottom, green) colocalized with the Golgi marker GM130 (red), suggesting localization to the Golgi apparatus similar to endogenous UGT1. In contrast, the p.Phe324Leufs*25 mutant (lower middle, green) was expressed in the cytosolic compartment, and expression of the p.Tyr145Profs*76 mutant (upper middle, green) was severely diminished. The nucleus was stained with DAPI (blue). The scale bars represent 10 μm .

the WT. In contrast, the p.Phe324Leufs*25 mutant was expressed in the cytosolic compartment and expression of the p.Tyr145Profs*76 mutant was severely diminished, suggesting that the function of the two truncated UGT1 proteins would be severely impaired (Fig. 2).

Because nucleotide-sugar transporters including UGT are critical components of glycosylation pathways such as *N*-glycosylation and *O*-glycosylation in eukaryotes, functional aberration of UGT is likely to affect protein glycosylation [Jaeken, 2003; Liu et al., 2010; Muntoni, 2004; Wopereis et al., 2006]. Therefore, we investigated glycosylation of serum glycoproteins isolated from the patients with a *SLC35A2* mutation, by isoelectric focusing, electrospray ionization, and matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) of transferrin and apolipoprotein CIII, and by MALDI-MS of immunoglobulin G (Supp. Figs. S3–S5 and Supp. Table S3). However, we could not detect any abnormalities of *N*-glycosylation or *O*-glycosylation in these serum glycoproteins. Considering that only WT *SLC35A2* is expressed in lymphoblastoid cells from the two patients, these normal glycosylation profiles of serum glycoproteins may be reasonable.

The clinical features of patients with a *SLC35A2* mutation are presented in Table 1. Dysmorphological findings such as thick eyebrows, a broad nasal bridge, thick lips, and maxillary prognathism were found (Fig. 3A–C). Brain magnetic resonance imaging (MRI) showed cerebral and cerebellar atrophy and thinning of the corpus callosum in two patients, 1 and 3, an arachnoid pouch in patient 1, and an enlarged left lateral ventricle in patient 2 (Fig. 3D–H). All patients were diagnosed as WS in their clinical course, and showed no abnormalities in the skin, coagulation, or hepatic enzymes, which are often observed in patients with CDG [Freeze, 2006; Freeze et al.,

2012]. On interictal EEG at 8 days after birth, patient 1 revealed brief tonic seizures of the upper extremities and a diffuse spike or sharp and slow-wave complex, which were accompanied by brief suppression for 1–2 sec (Fig. 3I). At 50 days, she showed a series of spasms, and the EEG transited to hypsarrhythmia at 2 months, leading to a diagnosis of WS. The administration of adrenocorticotrophic hormone (ACTH), zonisamide, and valproic acid (VPA) was temporarily effective; however, she developed seizures again at 4 months. Seizures were refractory to vitamin B6, phenobarbital, clobazam, corpus callosotomy, or a ketogenic diet. At 8 years of age, she showed hypotonia, severe intellectual disability, motor developmental delay, no head control, and no meaningful words. Patient 2 developed a series of spasms, and showed a diffuse spike or sharp and slow-wave complex on interictal EEG at 1 month. EEG transited to hypsarrhythmia at 4 months, leading to a diagnosis of WS. Her seizures were temporarily controlled by combined administration of VPA, nitrazepam, and ACTH, followed by low-dose ACTH therapy; however, spasms with clustering developed again at 6 years and 6 months. At 12 years, her spasms changed into focal seizures after administration of levetiracetam, and interictal EEG showed mainly slow waves with focal spikes. She could crawl on hands and knees and had severe intellectual disability with no meaningful words. Patient 3 started to have clusters of spasms at 3 months of age, and interictal EEG during sleep revealed hypsarrhythmia, leading to a diagnosis of early-onset WS (Fig. 3J). Vitamin B6 and VPA were ineffective at treating the spasms. Subsequent treatment with ACTH eliminated her spasms and hypsarrhythmia on EEG, but brief tonic seizures without clustering relapsed 1 month after the treatment. Despite the administration of various antiepileptic drugs

Table 1. Clinical Features of Patients with a *SLC35A2* Mutation

	Patient 1	Patient 2	Patient 3
Age	8 years 10 months	12 years 8 months	10 years 5 months
Gender	Female	Female	Female
Mutation	c.433_434del (p.Tyr145Profs*76)	c.972del (p.Phe324Leufs*25)	c.638C>T (p.Ser213Phe)
Diagnosis	EOEE → West syndrome	EOEE → West syndrome	Early-onset West syndrome
Initial symptom	Tonic seizure at 6 days	Spasms at 1 month	Spasms at 3 months
Initial EEG findings	Diffuse spike or sharp and slow-wave complex with brief suppression	Diffuse sharp or spike and slow-wave complex	Hypsarrhythmia
Transition of seizures	Spasms at 50 days, tonic seizure of upper extremities at 1 year 3 months	Generalized tonic seizure and spasm at 7 months, spasm at 6 years 6 months, focal seizure at 12 years	Brief tonic seizure, spasm at 1 year 6 months
Transition of EEG findings	Hypsarrhythmia at 2 months, multifocal spikes at 2 years	Hypsarrhythmia at 4 months, diffuse fast waves at 12 years	Multifocal spike and slow wave complex at 10 months
Seizure control	Intractable	Intractable	Intractable
Development	No head control, no words at 8 years	Crawling on hand and knees, no words at 12 years	No head control, no words at 10 years
Magnetic resonance imaging findings	Arachnoid pouch at 2 months, cerebral and cerebellar atrophy, thin corpus callosum, delayed myelination at 2 years	Normal at 2 months, spotty high-intensity signal in white matter, slight enlargement of left lateral ventricle at 4 years	Normal at 3 months, severe cortical atrophy, cerebellar atrophy, thin corpus callosum at 8 years
Craniofacial findings			
Coarse face	+	+	+
Thick eyebrows	+	+	+
Broad nasal bridge	+	+	+
Thick lips	+	+	+
Semi-open mouth	+	+	+
Prominent cupid's bow	-	+	+
Epicanthal folds	-	+	+
Short philtrum	-	+	+
Maxillary prognathism	+	+	+
Full cheek	-	-	+
Other	Fused tooth	High-arched palate	Enamel hypoplasia
Blood coagulation	Normal	Normal	Normal
Skin findings	Normal	Normal	Normal
Other features	Hypotonus	White spot in the eyeground, atrial septal defect ureteropelvic junction obstruction, vesicovaginal fistula	Hypotonic quadriplegia, hipdislocation

EOEE, early-onset epileptic encephalopathy; EEG, electroencephalography.

and a ketogenic diet, daily spasms with or without clustering have persisted. At the age of 10 years, she has attained no meaningful words or head control.

Discussion

In this study, we successfully identified three *de novo* heterozygous mutations in *SLC35A2* in patients with EOEE. Two mutations (p.Tyr145Profs*76 and p.Phe324Leufs*25) are predicted to cause truncation of UGT, suggesting that the function of the mutant protein would be severely impaired. Consistently, transient expression of mutant proteins in N2A cells revealed that the p.Phe324Leufs*25 mutant was not localized in the Golgi apparatus and that expression of the p.Tyr145Profs*76 mutant was severely diminished. Therefore, these two frameshift mutations are likely to cause loss of function in UGT. On the other hand, the p.Ser213Phe mutant was localized in the Golgi apparatus. A single amino acid deletion of Ser213 has been reported in hamster Ugt, which is highly homologous to human UGT (see Supp. Fig. S2). The hamster mutant failed to complement the defect of UDP-galactose transport in mutant Chinese hamster ovary lec8 cells, suggesting that the Ser213 residue is essential for proper UGT function [Oelmann et al., 2001]. Thus it is possible that the p.Ser213Phe mutation causes loss of function in the UGT, though further functional studies are required for clarifying pathogenicity of this missense allele.

Mutations in three nucleotide-sugar transporters have been previously reported to cause defects in glycan biosynthesis in humans: the GDP-fucose transporter encoded by *SLC35C1*, the CMP-sialic

acid transporter encoded by *SLC35A1*, and the UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter encoded by *SLC35D1* [Hiraoka et al., 2007; Liu et al., 2010; Lubke et al., 2001; Luhn et al., 2001; Martinez-Duncker et al., 2005]. Similarly, a defect in UGT would cause UDP-galactose deficiency in the ER-Golgi network, leading to reduced galactosylation of glycoproteins, glycosphingolipids, and proteoglycans [Liu et al., 2010]. In fact, three patients with *SLC35A2* mutations have been reported in association with galactosylation-deficient serum transferrin profiles in infancy: however, they showed normal serum transferrin profiles at 3–5 years [Ng et al., 2013]. Consistent with this, our three female cases showed no glycosylation abnormalities in the three commonly assayed serum glycoproteins at 8–10 years: transferrin and apolipoprotein CIII (mainly synthesized in the liver), and immunoglobulin G (synthesized by B lymphocytes) [Goreta et al., 2012; Okanishi et al., 2008; Wada et al., 2007, 2012]. In addition, DNA extracted from the leukocytes of patients 1 and 2 showed a markedly skewed X-inactivation, and only the WT *SLC35A2* allele was expressed in lymphoblastoid cell lines from these two patients. Therefore, although the degradation of mutant transcripts is a possible explanation for selective expression of WT allele, these findings raised a possibility that liver cells and B lymphocytes expressing the mutant allele are selected against during infancy, leading to no glycosylation defects in transferrin, apolipoprotein CIII, or immunoglobulin G in three patients, with a markedly skewed X-inactivation pattern in peripheral leukocytes.

The clinical features of the patients with a *SLC35A2* mutation seemed to be consistent with the negative selection of cells expressing the mutant allele. Specific skin features, coagulopathies,




Figure 3. Facial appearance, brain (MRI), and EEG of the three patients with a *SLC35A2* mutation. **A–C:** Photograph of patient 1 at 8 years of age (**A**), patient 2 at 12 years of age (**B**), and patient 3 at 10 years of age (**C**). Note the broad nasal bridge, thick eyebrows, thick lips, semi-open mouth, and maxillary prognathism that are common in these three patients. A fused tooth observed in patient 1 is indicated by an arrow (**A**, inset). **D and E:** T2-weighted MRI of patient 1 at 2 years and 4 months after corpus callosotomy showed cerebral atrophy on an axial image (**D**), and cerebellar atrophy and an arachnoid pouch (white arrow) on a sagittal image (**E**). **F:** A T2-weighted axial image of patient 2 at 4 years and 3 months showed slight enlargement of the left lateral ventricle. **G and H:** T2-weighted MRI of patient 3 at 7 years showed cerebral atrophy with frontal lobe predominance on an axial image (**G**), and cerebellar atrophy and a thin corpus callosum (white arrowheads) on a sagittal image (**H**). **I:** Interictal EEG of patient 1 during sleep at 1.5 months old showing diffuse spike or sharp and slow-wave complexes, which were accompanied by brief suppression for 1–2 sec. **J:** Interictal EEG of patient 3 during sleep at 3 months old showing hypersarrrhythmia.

immune dysfunction, cardiomyopathy, and renal dysfunction, which are often observed in glycosylation disorders [Freeze et al., 2012], were not found in these three patients, although they did present epileptic seizures (EOEE). Thus, it can be hypothesized that cells expressing the mutant allele were excluded in most organs but not the central nervous system, where a substantial number of neurons might express the mutant *SLC35A2* allele and suffer from defective galactosylation of glycoproteins, glycosphingolipids, and proteoglycans.

Together with a recent report [Ng et al., 2013], our data suggest that abnormal glycosylation may be one of the underlying pathologies of EOEE. In the absence of glycosylation abnormalities, similar to our three cases, a UGT disorder can only be diagnosed by the identification of a *SLC35A2* mutation. Recent progress in massively parallel DNA sequencing in combination with whole-exome capturing (WES) has facilitated rapid mutation detection in most exons [Bamshad et al., 2011]. WES is expected to be useful for genetic

testing in EOEE, and is likely to reveal contributions from hitherto unexpected genes.

Conclusion

We identified de novo heterozygous mutations in the X-linked *SLC35A2* gene, which encodes the UGT, in patients with EOEE. Our data confirmed that abnormal glycosylation is one of the pathological features of EOEE.

Acknowledgments

The authors would like to thank all patients and their families for their participation in this study. We also thank Aya Narita and Nobuko Watanabe for technical assistance.

Disclosure statement: The authors declare no conflicts of interest.

References

- Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, Shendure J. 2011. Exome sequencing as a tool for Mendelian disease gene discovery. *Nat Rev Genet* 12:745–755.
- Barcia G, Fleming MR, Deligniere A, Gazula VR, Brown MR, Langouet M, Chen H, Kronengold J, Abhyankar A, Cilio R, Nitschke P, Kaminska A, et al. 2012. *De novo* gain-of-function *KCNT1* channel mutations cause malignant migrating partial seizures of infancy. *Nat Genet* 44:1255–1259.
- Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. 2001. *De novo* mutations in the sodium-channel gene *SCN1A* cause severe myoclonic epilepsy of infancy. *Am J Hum Genet* 68:1327–32.
- DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, et al. 2011. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet* 43:491–498.
- Freeze HH. 2006. Genetic defects in the human glycome. *Nat Rev Genet* 7:537–551.
- Freeze HH. 2013. Understanding human glycosylation disorders: biochemistry leads the charge. *J Biol Chem* 288:6936–6945.
- Freeze HH, Eklund EA, Ng BG, Patterson MC. 2012. Neurology of inherited glycosylation disorders. *Lancet Neurol* 11:453–466.
- Goreta SS, Dabelic S, Dumic J. 2012. Insights into complexity of congenital disorders of glycosylation. *Biochem Med (Zagreb)* 22:156–170.
- Hiraoka S, Furuichi T, Nishimura G, Shibata S, Yanagishita M, Rimoin DL, Superti-Furga A, Nikkels PG, Ogawa M, Katsuyama K, Toyoda H, Kinoshita-Toyoda A, et al. 2007. Nucleotide-sugar transporter *SLC35D1* is critical to chondroitin sulfate synthesis in cartilage and skeletal development in mouse and human. *Nat Med* 13:1363–1367.
- Holland KD, Hallinan BE. 2010. What causes epileptic encephalopathy in infancy?: the answer may lie in our genes. *Neurology* 75:1132–1133.
- Hu H, Eggers K, Chen W, Garshabi M, Motazacker MM, Wroegemann K, Kahrizi K, Tzschach A, Hosseini M, Bahman I, Hucho T, Mühlenhoff M, et al. 2011. *ST3GAL3* mutations impair the development of higher cognitive functions. *Am J Hum Genet* 89:407–414.
- Ishida N, Miura N, Yoshioka S, Kawakita M. 1996. Molecular cloning and characterization of a novel isoform of the human UDP-galactose transporter, and of related complementary DNAs belonging to the nucleotide-sugar transporter gene family. *J Biochem* 120:1074–1078.
- Jaeken J. 2003. Komrower Lecture. Congenital disorders of glycosylation (CDG): it's all in it! *J Inher Metab Dis* 26:99–118.
- Jaeken J, Matthijs G. 2007. Congenital disorders of glycosylation: a rapidly expanding disease family. *Annu Rev Genomics Hum Genet* 8:261–278.
- Kabuss R, Ashikov A, Oelmann S, Gerardy-Schahn R, Bakker H. 2005. Endoplasmic reticulum retention of the large splice variant of the UDP-galactose transporter is caused by a dilysine motif. *Glycobiology* 15:905–911.
- Kalscheuer VM, Tao J, Donnelly A, Holloway G, Schwinger E, Kubart S, Menzel C, Hoeltzenbein M, Tommerup N, Eyre H, Harbord M, Haan E, Sutherland GR, Ropers HH, Gécz J. 2003. Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. *Am J Hum Genet* 72:1401–1411.
- Kato M, Saitoh S, Kamei A, Shiraiishi H, Ueda Y, Akasaka M, Tohyama J, Akasaka N, Hayasaka K. 2007. A longer polyalanine expansion mutation in the *ARX* gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). *Am J Hum Genet* 81:361–366.
- Kondo Y, Saito H, Miyamoto T, Nishiyama K, Tsurusaki Y, Doi H, Miyake N, Ryoo NK, Kim JH, Yu YS, and others. 2012. A family of oculofaciocardiodental syndrome (OFCD) with a novel *BCOR* mutation and genomic rearrangements involving *NHS*. *J Hum Genet* 57:197–201.
- Kurian MA, Meyer E, Vassallo G, Morgan NV, Prakash N, Pasha S, Hai NA, Shuib S, Rahman F, Wassmer E, Cross JH, O'Callaghan FJ, et al. 2010. Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy. *Brain* 133:2964–2970.
- Liu L, Xu YX, Hirschberg CB. 2010. The role of nucleotide sugar transporters in development of eukaryotes. *Semin Cell Dev Biol* 21:600–608.
- Lubke T, Marquardt T, Etzioni A, Hartmann E, von Figura K, Korner C. 2001. Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. *Nat Genet* 28:73–76.
- Luhn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D. 2001. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. *Nat Genet* 28:69–72.
- Martinez-Duncker I, Dupre T, Piller V, Piller F, Candelier JJ, Trichet C, Tchernia G, Oriol R, Mollicone R. 2005. Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter. *Blood* 105:2671–2676.
- Mills PB, Surtees RA, Champion MP, Beesley CE, Dalton N, Scambler PJ, Heales SJ, Briddon A, Scheimberg I, Hoffmann GF, Zschocke J, Clayton PT. 2005. Neonatal epileptic encephalopathy caused by mutations in the *PNPO* gene encoding pyridox(am)ine 5'-phosphate oxidase. *Hum Mol Genet* 14:1077–1086.
- Miura N, Ishida N, Hoshino M, Yamauchi M, Hara T, Ayusawa D, Kawakita M. 1996. Human UDP-galactose translocator: molecular cloning of a complementary DNA that complements the genetic defect of a mutant cell line deficient in UDP-galactose translocator. *J Biochem* 120:236–241.
- Molinari F, Raas-Rothschild A, Rio M, Fiermonte G, Encha-Razavi F, Palmieri L, Palmieri F, Ben-Neriah Z, Kadhom N, Vekemans M, Attie-Bitach T, Munnich A, Rustin P, Colleaux L. 2005. Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. *Am J Hum Genet* 76:334–339.
- Muntoni F. 2004. Journey into muscular dystrophies caused by abnormal glycosylation. *Acta Myol* 23:79–84.
- Ng BG, Buckingham KJ, Raymond K, Kircher M, Turner EH, He M, Smith JD, Eroshkin A, Szybowska M, Losfeld ME, Chong JX, Kozenko M, et al. 2013. Mosaicism of the UDP-galactose transporter *SLC35A2* causes a congenital disorder of glycosylation. *Am J Hum Genet* 92:632–636.
- Oelmann S, Stanley P, Gerardy-Schahn R. 2001. Point mutations identified in Lec8 Chinese hamster ovary glycosylation mutants that inactivate both the UDP-galactose and CMP-sialic acid transporters. *J Biol Chem* 276:26291–26300.
- Okanishi T, Saito Y, Yuasa I, Miura M, Nagata I, Maegaki Y, Ohno K. 2008. Cutis laxa with frontoparietal cortical malformation: a novel type of congenital disorder of glycosylation. *Eur J Paediatr Neurol* 12:262–265.
- Saito H, Kato M, Koide A, Goto T, Fujita T, Nishiyama K, Tsurusaki Y, Doi H, Miyake N, Hayasaka K, Matsumoto N. 2012a. Whole exome sequencing identifies *KCNQ2* mutations in Ohtahara syndrome. *Ann Neurol* 72:298–300.
- Saito H, Kato M, Mizuguchi T, Hamada K, Osaka H, Tohyama J, Urano K, Kumada S, Nishiyama K, Nishimura A, Okada A, Yoshimura Y, et al. 2008. *De novo* mutations in the gene encoding *STXBP1* (*MUNC18-1*) cause early infantile epileptic encephalopathy. *Nat Genet* 40:782–788.
- Saito H, Kato M, Okada I, Orii KE, Higuchi T, Hoshino H, Kubota M, Arai H, Tagawa T, Kimura S, Sudo A, Miyama S, et al. 2010. *STXBP1* mutations in early infantile epileptic encephalopathy with suppression-burst pattern. *Epilepsia* 51:2397–2405.
- Saito H, Kato M, Osaka H, Moriyama N, Horita H, Nishiyama K, Yoneda Y, Kondo Y, Tsurusaki Y, Doi H, Miyake N, Hayasaka K, Matsumoto N. 2012b. *CASK* aberrations in male patients with Ohtahara syndrome and cerebellar hypoplasia. *Epilepsia* 53:1441–1449.
- Saito H, Nishimura T, Muramatsu K, Kodera H, Kumada S, Sugai K, Kasai-Yoshida E, Sawaura N, Nishida H, Hoshino A, Ruyjin F, Yoshioka S, et al. 2013. *De novo* mutations in the autophagy gene *WDR45* cause static encephalopathy of childhood with neurodegeneration in adulthood. *Nat Genet* 45:445–449.
- Shen J, Gilmore EC, Marshall CA, Haddadin M, Reynolds JJ, Eyaid W, Bodell A, Barry B, Gleason D, Allen K, Ganesh VS, Chang BS, et al. 2010. Mutations in *PNKP* cause microcephaly, seizures and defects in DNA repair. *Nat Genet* 42:245–249.
- Stromme P, Mangelsdorf ME, Shaw MA, Lower KM, Lewis SM, Bruyere H, Lucherath V, Gedeon AK, Wallace RH, Scheffer IE, Turner G, Partington M, et al. 2002. Mutations in the human ortholog of *Aristaless* cause X-linked mental retardation and epilepsy. *Nat Genet* 30:441–445.
- Wada Y, Azadi P, Costello CE, Dell A, Dwek RA, Geyer H, Geyer R, Kakehi K, Karlsson NG, Kato K, Kawasaki N, Khoo KH, et al. 2007. Comparison of the methods for profiling glycoprotein glycans—HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. *Glycobiology* 17:411–422.
- Wada Y, Kadoya M, Okamoto N. 2012. Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (*ARCL2*) patient. *Glycobiology* 22:1140–1144.
- Wang K, Li M, Hakonarson H. 2010. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 38:e164.
- Weckhuysen S, Mandelstam S, Suls A, Audenaert D, Deconinck T, Claes LR, Deprez L, Smets K, Hristova D, Yordanova I, Jordanova A, Ceulemans B, et al. 2012. *KCNQ2* encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. *Ann Neurol* 71:15–25.
- Wopereis S, Lefeber DJ, Morava E, Wevers RA. 2006. Mechanisms in protein O-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review. *Clin Chem* 52:574–600.
- Yoshioka S, Sun-Wada GH, Ishida N, Kawakita M. 1997. Expression of the human UDP-galactose transporter in the Golgi membranes of murine Had-1 cells that lack the endogenous transporter. *J Biochem* 122:691–695.

Identification of *KLHL41* Mutations Implicates BTB-Kelch-Mediated Ubiquitination as an Alternate Pathway to Myofibrillar Disruption in Nemaline Myopathy

Vandana A. Gupta,¹ Gianina Ravenscroft,² Ranad Shaheen,³ Emily J. Todd,² Lindsay C. Swanson,¹ Masaaki Shiina,⁴ Kazuhiro Ogata,⁴ Cynthia Hsu,¹ Nigel F. Clarke,⁵ Basil T. Darras,⁶ Michelle A. Farrar,⁷ Amal Hashem,³ Nicholas D. Manton,⁸ Francesco Muntoni,⁹ Kathryn N. North,¹⁰ Sarah A. Sandaradura,⁵ Ichizo Nishino,¹¹ Yukiko K. Hayashi,¹¹ Caroline A. Sewry,⁹ Elizabeth M. Thompson,^{12,13} Kyle S. Yau,² Catherine A. Brownstein,¹ Timothy W. Yu,¹ Richard J.N. Allcock,¹⁴ Mark R. Davis,¹⁵ Carina Wallgren-Pettersson,¹⁶ Naomichi Matsumoto,¹⁷ Fowzan S. Alkuraya,³ Nigel G. Laing,² and Alan H. Beggs^{1,*}

Nemaline myopathy (NM) is a rare congenital muscle disorder primarily affecting skeletal muscles that results in neonatal death in severe cases as a result of associated respiratory insufficiency. NM is thought to be a disease of sarcomeric thin filaments as six of eight known genes whose mutation can cause NM encode components of that structure, however, recent discoveries of mutations in non-thin filament genes has called this model in question. We performed whole-exome sequencing and have identified recessive small deletions and missense changes in the Kelch-like family member 41 gene (*KLHL41*) in four individuals from unrelated NM families. Sanger sequencing of 116 unrelated individuals with NM identified compound heterozygous changes in *KLHL41* in a fifth family. Mutations in *KLHL41* showed a clear phenotype-genotype correlation: Frameshift mutations resulted in severe phenotypes with neonatal death, whereas missense changes resulted in impaired motor function with survival into late childhood and/or early adulthood. Functional studies in zebrafish showed that loss of *Klhl41* results in highly diminished motor function and myofibrillar disorganization, with nemaline body formation, the pathological hallmark of NM. These studies expand the genetic heterogeneity of NM and implicate a critical role of BTB-Kelch family members in maintenance of sarcomeric integrity in NM.

Nemaline myopathy (NM) is a rare congenital disorder primarily affecting skeletal muscle function. Clinically, NM is a heterogeneous group of myopathies of variable severity.^{1,2} The “severe” congenital form of NM presents with reduced or absent spontaneous movements in utero leading to severe contractures or fractures at birth and respiratory insufficiency leading to early mortality. Individuals with the “intermediate” congenital form of NM have antigravity movement and independent respiration at delivery but exhibit delayed motor milestones and require ventilatory support later in life. The “typical” congenital form of NM usually presents in the neonatal period or first year of life with hypotonia, weakness, and feeding difficulties with less prominent respiratory involvement. In these cases, the disease is usually static

or very slowly progressive, and many individuals remain ambulant for much of their lives.³ The defining diagnostic feature of all forms of NM, irrespective of genetic mutation, is the presence of numerous red-staining rods with Gomori trichrome stain that appear as rod-shaped electron-dense structures termed “nemaline bodies” by electron microscopy.⁴ These nemaline bodies are most frequently cytoplasmic; however, the presence of intranuclear rods has also been reported.⁵

NM is a genetically heterogeneous condition, and mutations in eight different genes have been identified that are associated with dominant and/or recessive forms of this disease.^{6–13} Mutations in these genes cause about 75%–80% of NM cases, suggesting the involvement of additional unidentified genes in disease etiology.

¹Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA; ²Western Australian Institute for Medical Research and the Centre for Medical Research, University of Western Australia, Nedlands, Western Australia 6009, Australia; ³Developmental Genetics Unit, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia; ⁴Department of Biochemistry, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan; ⁵Institute for Neuroscience and Muscle Research, Children’s Hospital at Westmead and Discipline of Paediatrics and Child Health, University of Sydney, Sydney 2145, Australia; ⁶Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA; ⁷Department of Neurology, Sydney Children’s Hospital, Randwick NSW 2032, Australia; ⁸Department of Surgical Pathology, SA Pathology at the Women’s and Children’s Hospital, North Adelaide, South Australia 5006; ⁹Dubowitz Neuromuscular Centre, Institute of Child Health and Great Ormond Street Hospital, London WC1N 1EH, UK; ¹⁰Murdoch Childrens Research Institute, The Royal Children’s Hospital, Parkville, Victoria 3052, Australia; ¹¹Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8502, Japan; ¹²Department of Paediatrics, University of Adelaide, Adelaide, South Australia 5000, Australia; ¹³SA Clinical Genetics Service, SA Pathology at the Women’s and Children’s Hospital, North Adelaide, South Australia 5006, Australia; ¹⁴Lotterywest State Biomedical Facility Genomics and School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia 6000, Australia; ¹⁵Department of Anatomical Pathology, Royal Perth Hospital, Perth, Western Australia 6000, Australia; ¹⁶The Folkhälsan Institute of Genetics, Samfundet Folkhälsan, Biomedicum Helsinki, PB 63 (Haartmaninkatu 8), and Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki 00014, Finland; ¹⁷Department of Human Genetics, Yokohama City University, Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan

*Correspondence: beggs@enders.tch.harvard.edu

<http://dx.doi.org/10.1016/j.ajhg.2013.10.020>. ©2013 by The American Society of Human Genetics. All rights reserved.